| TUSIRG Boehringer Ingelheim International GmbH
2349339 01 Aug 2024 | on 12 Sep 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism, namely, renal diseases, liver diseases, pancreas diseases, digestive system disorders, gastrointestinal diseases and disorders, obesity; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs, namely, vascular diseases, hematology, blood disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, central nervous system diseases and disorders, peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues, namely, rashes, sores, psoriasis, eczema; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections, namely, antibiotics, anti-infectives, antivirals; pharmaceutical preparations for the prevention and treatment of oncological diseases; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of immunological diseases, namely, autoimmune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of infectious diseases, namely viral infections. | |